Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Role of Adiponectin and Endothelial Progenitor Cells in Reperfusion Injury in Patients With Acute Myocardial Infarction (R²ACE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
M Claeys, Universiteit Antwerpen
ClinicalTrials.gov Identifier:
NCT01414452
First received: August 10, 2011
Last updated: March 15, 2014
Last verified: March 2014

August 10, 2011
March 15, 2014
April 2011
December 2012   (final data collection date for primary outcome measure)
occurrence of reperfusion injury after succesfull primary PCI [ Time Frame: within 90 min after PCI ] [ Designated as safety issue: No ]
Serial ECG measurements (before and after PCI to assess extent of ST segment resolution as marker of reperfusion injury
Same as current
Complete list of historical versions of study NCT01414452 on ClinicalTrials.gov Archive Site
Major cardiovascular event rate [ Time Frame: at 1 year ] [ Designated as safety issue: Yes ]
combined endpoint of hospitalisation (or extension of hospitalisation) for heart failure and cardiac death in a period of one year
Same as current
Not Provided
Not Provided
 
Role of Adiponectin and Endothelial Progenitor Cells in Reperfusion Injury in Patients With Acute Myocardial Infarction
Reperfusion Injury and Cardiac Remodelling After Myocardial Infarction in Relation to Adiponectin Level, Circulating Endothelial Progenitor Cells and Endothelial Microparticles

There is experimental evidence that low levels of adiponectin are associated with more reperfusion injury. In addition experimental studies have demonstrated that endothelial progenitor cells may have a favorable effect on remodeling, mainly through stimulation of neo-revascularisation. Clinical data on these issues are lacking. This clinical project studies the role of adiponectin, endothelial progenitor cells and endothelial microparticles in the ischaemia-reperfusion process and the compensatory ventricular remodelling in a population of 250 infarction patients treated with primary PCI. If the role of these factors could be confirmed in this clinical setting, those factors might represent a new target for therapeutic interventions in AMI patients.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

blood samples

Probability Sample

ST elevetion myocardial infarction patients

  • Myocardial Infarction
  • Reperfusion Injury
Not Provided
STEMI patients
Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
December 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • STEMI treated with primary PCI

Exclusion Criteria:

  • ischemia time >12h
  • use of immunosuppressive therapy
  • unsuccessful recanalisation
  • not-interpretable ST-T segment
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT01414452
UAntwerpen
No
M Claeys, Universiteit Antwerpen
Universiteit Antwerpen
Not Provided
Not Provided
Universiteit Antwerpen
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP